Bruce Alan Kaplan, MD in Ketchum, ID - Medicare Plastic Surgery

Bruce Alan Kaplan, MD is a medicare enrolled "Plastic Surgery" physician in Ketchum, Idaho. His current practice location is 190 Bigwood Drive South, Ketchum, Idaho. You can reach out to his office (for appointments etc.) via phone at (208) 725-5094.

Bruce Alan Kaplan is licensed to practice in Idaho (license number M-5534) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1467704049.

Contact Information

	Bruce Alan Kaplan, MD
	190 Bigwood Drive South, Ketchum, ID 83340
	(208) 725-5094
	Not Available

Physician's Profile

Full Name	Bruce Alan Kaplan
Gender	Male
Speciality	Plastic Surgery
Location	190 Bigwood Drive South, Ketchum, Idaho
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1467704049
Provider Enumeration Date: 10/08/2012
Last Update Date: 10/08/2012

Medicare PECOS Information:

PECOS PAC ID: 3274822739
Enrollment ID: I20160523001968

Medical Identifiers

Medical identifiers for Bruce Alan Kaplan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1467704049	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208200000X	Plastic Surgery	M-5534 (Idaho)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Bruce Alan Kaplan is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Bruce Alan Kaplan, MD Po Box 2187, Sun Valley, ID 83353-2187 Ph: (208) 725-5094	Bruce Alan Kaplan, MD 190 Bigwood Drive South, Ketchum, ID 83340 Ph: (208) 725-5094

News Archive

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.

Leg cramps could be a sign of peripheral artery disease

Peripheral artery disease develops silently, narrowing blood vessels for decades until the supply of nutrients and oxygen falls low enough to cause cramps and leg pain.

St. Jude scientists develop interactive tool to advance understanding of mutations that fuel pediatric cancer

St. Jude Children's Research Hospital scientists have developed a web application and data set that gives researchers worldwide a powerful interactive tool to advance understanding of the mutations that lead to and fuel pediatric cancer. The freely available tool, called ProteinPaint, is described in today's issue of the scientific journal Nature Genetics.

Children receiving living donor liver transplant less likely to experience organ rejection

In the United States alone, 500 children will need a liver transplant this year. While liver tissue can come from living or deceased donors, no studies have demonstrated which of these methods leads to better outcomes for children. In a new publication, researchers at Children's Hospital Los Angeles pooled published results from over 8,000 pediatric patients across four continents. The data reveal that children who receive living donor liver tissue for transplants are far less likely to experience serious complications like organ rejection.

Bile duct cancer chosen as next indication for PCI Biotech

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has chosen bileduct cancer as the next indication for the use of its PCI (photochemical internalisation) localised cancer therapy. In this indication PCI Biotech's proprietary photosensitiser Amphinex® will be used in combination with the generic cytotoxic agent gemcitabine. The aim is to start the clinical Proof of Concept study within end of 1H 2013.

Bruce Alan Kaplan, MD - Medicare Plastic Surgery in Ketchum, ID